EPS for Core Laboratories N.V. (CLB) Expected At $0.58

March 16, 2018 - By Louis Casey

 EPS for Core Laboratories N.V. (CLB) Expected At $0.58
Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.01, from 1.08 in 2017Q2. It worsened, as 45 investors sold Core Laboratories N.V. shares while 99 reduced holdings. 42 funds opened positions while 112 raised stakes. 49.25 million shares or 6.07% more from 46.43 million shares in 2017Q2 were reported.
1,412 were reported by Shine Inv Advisory Svcs Inc. First Manhattan invested in 175 shares or 0% of the stock. Paloma Mgmt stated it has 2,129 shares or 0% of all its holdings. Mitsubishi Ufj & accumulated 0.02% or 113,264 shares. Schwab Charles Investment Mgmt, a California-based fund reported 147,397 shares. Blackrock Inc has invested 0.02% in Core Laboratories N.V. (NYSE:CLB). Legal General Group Inc Public Ltd Com accumulated 0.02% or 213,309 shares. Underhill Inv Limited Com invested in 2.27% or 42,460 shares. Btim Corporation reported 74,430 shares. Lpl Fin has invested 0% in Core Laboratories N.V. (NYSE:CLB). Congress Asset Company Ma holds 0.01% of its portfolio in Core Laboratories N.V. (NYSE:CLB) for 7,225 shares. Nomura Incorporated owns 5,281 shares for 0% of their portfolio. Solaris Asset Management Limited Co holds 0.02% or 305 shares. Fdx Advisors stated it has 16,402 shares. Connable Office reported 0.22% in Core Laboratories N.V. (NYSE:CLB).

Analysts expect Core Laboratories N.V. (NYSE:CLB) to report $0.58 EPS on April, 18.They anticipate $0.16 EPS change or 38.10 % from last quarter’s $0.42 EPS. CLB’s profit would be $25.62M giving it 45.42 P/E if the $0.58 EPS is correct. After having $0.58 EPS previously, Core Laboratories N.V.’s analysts see 0.00 % EPS growth. The stock decreased 2.37% or $2.56 during the last trading session, reaching $105.38. About 411,713 shares traded. Core Laboratories N.V. (NYSE:CLB) has declined 5.82% since March 16, 2017 and is downtrending. It has underperformed by 22.52% the S&P500.

Core Laboratories N.V. (NYSE:CLB) Ratings Coverage

Among 23 analysts covering Core Laboratories (NYSE:CLB), 12 have Buy rating, 0 Sell and 11 Hold. Therefore 52% are positive. Core Laboratories had 53 analyst reports since August 24, 2015 according to SRatingsIntel. As per Thursday, September 1, the company rating was initiated by Credit Suisse. The firm has “Neutral” rating given on Wednesday, October 25 by UBS. RBC Capital Markets maintained the stock with “Buy” rating in Monday, January 29 report. Morgan Stanley maintained it with “Overweight” rating and $125 target in Monday, August 7 report. Loop Capital upgraded the stock to “Buy” rating in Friday, April 21 report. The stock of Core Laboratories N.V. (NYSE:CLB) earned “Outperform” rating by RBC Capital Markets on Thursday, January 28. As per Tuesday, December 13, the company rating was initiated by UBS. The company was maintained on Monday, May 16 by Citigroup. The stock of Core Laboratories N.V. (NYSE:CLB) earned “Hold” rating by Cowen & Co on Friday, October 6. Citigroup maintained the shares of CLB in report on Wednesday, July 26 with “Neutral” rating.

Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services to the gas and oil industry in the United States, Canada, and internationally. The company has market cap of $4.65 billion. It operates through three divisions: Reservoir Description, Production Enhancement, and Reservoir Management. It has a 56.05 P/E ratio. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples.

More news for Core Laboratories N.V. (NYSE:CLB) were recently published by: Prnewswire.com, which released: “What’s Happening With These Oil & Gas Stocks? — CARBO Ceramics, Core …” on February 21, 2018. Nasdaq.com‘s article titled: “Core Laboratories Reaches Analyst Target Price” and published on February 23, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.